These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 28987930)

  • 21. Tandem autologous non-myeloablative allogeneic transplantation in patients with multiple myeloma relapsing after a first high dose therapy.
    Karlin L; Arnulf B; Chevret S; Ades L; Robin M; De Latour RP; Malphettes M; Kabbara N; Asli B; Rocha V; Fermand JP; Socie G
    Bone Marrow Transplant; 2011 Feb; 46(2):250-6. PubMed ID: 20400980
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-Term Follow-Up of a Donor versus No-Donor Comparison in Patients with Multiple Myeloma in First Relapse after Failing Autologous Transplantation.
    Patriarca F; Bruno B; Einsele H; Spina F; Giaccone L; Montefusco V; Isola M; Nozzoli C; Nozza A; Morabito F; Corradini P; Fanin R
    Biol Blood Marrow Transplant; 2018 Feb; 24(2):406-409. PubMed ID: 29032267
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of upfront tandem autologous-allogeneic transplantation versus reduced intensity allogeneic transplantation for multiple myeloma.
    Sahebi F; Iacobelli S; Biezen AV; Volin L; Dreger P; Michallet M; Ljungman PT; de Witte T; Henseler A; Schaap NP; López-Corral L; Poire X; Passweg J; Hamljadi RM; Thomas SH; Schonland S; Gahrton G; Morris C; KrÖger N; Garderet L
    Bone Marrow Transplant; 2015 Jun; 50(6):802-7. PubMed ID: 25798673
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chemotherapy versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplant.
    Motabi IH; Ghobadi A; Liu J; Schroeder M; Abboud CN; Cashen AF; Stockler-Goldstein KE; Uy GL; Vij R; Westervelt P; DiPersio JF
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1324-1329. PubMed ID: 27026249
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extramedullary vs medullary relapse after autologous or allogeneic hematopoietic stem cell transplantation (HSCT) in multiple myeloma (MM) and its correlation to clinical outcome.
    Zeiser R; Deschler B; Bertz H; Finke J; Engelhardt M
    Bone Marrow Transplant; 2004 Dec; 34(12):1057-65. PubMed ID: 15516937
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous transplantation: a study by the European Group for Blood and Marrow Transplantation.
    Auner HW; Szydlo R; van Biezen A; Iacobelli S; Gahrton G; Milpied N; Volin L; Janssen J; Nguyen Quoc S; Michallet M; Schoemans H; El Cheikh J; Petersen E; Guilhot F; Schönland S; Ahlberg L; Morris C; Garderet L; de Witte T; Kröger N;
    Bone Marrow Transplant; 2013 Nov; 48(11):1395-400. PubMed ID: 23708704
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study.
    Rigacci L; Puccini B; Dodero A; Iacopino P; Castagna L; Bramanti S; Ciceri F; Fanin R; Rambaldi A; Falda M; Milone G; Guidi S; Martelli MF; Mazza P; Oneto R; Bosi A;
    Ann Hematol; 2012 Jun; 91(6):931-9. PubMed ID: 22245922
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of umbilical cord blood allogeneic stem cell transplantation vs. auto-SCT for adult acute myeloid leukemia patients in second complete remission at transplant: a retrospective study on behalf of the SFGM-TC.
    Chevallier P; Labopin M; Socie G; Rubio MT; Blaise D; Vigouroux S; Huynh A; Michallet M; Bay JO; Maury S; Yakoub-Agha I; Fegueux N; Deconinck E; Contentin N; Maillard N; Bulabois CE; Francois S; Oumedaly R; Raus N; Mohty M
    Eur J Haematol; 2015 May; 94(5):449-55. PubMed ID: 25238651
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison between autologous and allogeneic stem cell transplantation as salvage therapy for multiple myeloma relapsing/progressing after autologous stem cell transplantation.
    Ikeda T; Mori K; Kawamura K; Mori T; Hagiwara S; Ueda Y; Kahata K; Uchida N; Tsukada N; Murakami S; Yamamoto M; Takahashi T; Ichinohe T; Onizuka M; Atsuta Y; Kanda Y; Okamoto S; Sunami K; Takamatsu H
    Hematol Oncol; 2019 Dec; 37(5):586-594. PubMed ID: 31674032
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival.
    Dhakal B; D'Souza A; Martens M; Kapke J; Harrington AM; Pasquini M; Saber W; Drobyski WR; Zhang MJ; Hamadani M; Hari PN
    Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):379-86. PubMed ID: 27160644
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of relapse after transplantation in acute leukemia: A comparative on second allogeneic hematopoietic cell transplantation and donor lymphocyte infusions.
    Ortí G; Sanz J; García-Cadenas I; Sánchez-Ortega I; Alonso L; Jiménez MJ; Sisinni L; Azqueta C; Salamero O; Badell I; Ferra C; de Heredia CD; Parody R; Sanz MA; Sierra J; Piñana JL; Querol S; Valcárcel D
    Exp Hematol; 2018 Jun; 62():24-32. PubMed ID: 29526774
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Autologous and allogeneic transplantation for multiple myeloma at a single centre.
    Couban S; Stewart AK; Loach D; Panzarella T; Meharchand J
    Bone Marrow Transplant; 1997 Apr; 19(8):783-9. PubMed ID: 9134169
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic factors and outcome in relapsed multiple myeloma after nonmyeloablative allo-SCT: a single center experience.
    Minnema MC; van Dorp S; van de Donk NW; Schouten F; Kersten MJ; Coenen JL; Schouten H; Zweegman S; Schaafsma R; Lokhorst HM
    Bone Marrow Transplant; 2011 Feb; 46(2):244-9. PubMed ID: 20400982
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies.
    Branson K; Chopra R; Kottaridis PD; McQuaker G; Parker A; Schey S; Chakraverty RK; Craddock C; Milligan DW; Pettengell R; Marsh JC; Linch DC; Goldstone AH; Williams CD; Mackinnon S
    J Clin Oncol; 2002 Oct; 20(19):4022-31. PubMed ID: 12351600
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma.
    Afrough A; Alsfeld LC; Milton DR; Delgado R; Popat UR; Nieto Y; Kebriaei P; Oran B; Saini N; Srour S; Hosing C; Cheema FH; Ahmed S; Manasanch EE; Lee HC; Kaufman GP; Patel KK; Weber DM; Orlowski RZ; Pinnix CC; Dabaja BS; Thomas SK; Champlin RE; Shpall EJ; Qazilbash MH; Bashir Q
    Transplant Cell Ther; 2023 Apr; 29(4):264.e1-264.e9. PubMed ID: 35605883
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma.
    Kröger N; Badbaran A; Zabelina T; Ayuk F; Wolschke C; Alchalby H; Klyuchnikov E; Atanackovic D; Schilling G; Hansen T; Schwarz S; Heinzelmann M; Zeschke S; Bacher U; Stübig T; Fehse B; Zander AR
    Biol Blood Marrow Transplant; 2013 Mar; 19(3):398-404. PubMed ID: 23078786
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Focus on Longitudinal Assessment of Donor Chimerism, Extramedullary Disease, and High-Risk Cytogenetic Features.
    Rasche L; Röllig C; Stuhler G; Danhof S; Mielke S; Grigoleit GU; Dissen L; Schemmel L; Middeke JM; Rücker V; Schreder M; Schetelig J; Bornhäuser M; Einsele H; Thiede C; Knop S
    Biol Blood Marrow Transplant; 2016 Nov; 22(11):1988-1996. PubMed ID: 27590108
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evolving strategies with immunomodulating drugs and tandem autologous/allogeneic hematopoietic stem cell transplantation in first line high risk multiple myeloma patients.
    Michallet M; Sobh M; El-Cheikh J; Morisset S; Sirvent A; Reman O; Cornillon J; Tabrizi R; Milpied N; Harousseau JL; Labussière H; Nicolini FE; Attal M; Moreau P; Mohty M; Blaise D; Avet-Loiseau H
    Exp Hematol; 2013 Dec; 41(12):1008-15. PubMed ID: 23994781
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse.
    Kharfan-Dabaja MA; Labopin M; Polge E; Nishihori T; Bazarbachi A; Finke J; Stadler M; Ehninger G; Lioure B; Schaap N; Afanasyev B; Yeshurun M; Isaksson C; Maertens J; Chalandon Y; Schmid C; Nagler A; Mohty M
    JAMA Oncol; 2018 Sep; 4(9):1245-1253. PubMed ID: 30003233
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.
    Le Bourgeois A; Mohr C; Guillaume T; Delaunay J; Malard F; Loirat M; Peterlin P; Blin N; Dubruille V; Mahe B; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Lode L; Bene MC; Chevallier P
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):934-9. PubMed ID: 23523970
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.